Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

nt with FDA on the design of a second Phase 3 registration trial featuring pain palliation via the SPA process. OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

OncoGenex holds an exclusive license for patents related to clusterin inhibition obtained from the University of British Columbia based on discoveries made by researchers at the Prostate Centre at Vancouver General Hospital. OGX-011 utilizes second generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of clusterin protein in tumor cells. OncoGenex and Isis partnered in the successful discovery and initial development of OGX-011 and, in 2008, amended their agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development costs and partnering decisions, subject to financial obligations to Isis.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.

'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
(Date:7/24/2014)...  Neogen Corporation (Nasdaq: NEOG ) advised ... revenue from new rodenticide research are premature. In its ... July 22, 2014, Neogen,s CEO commented about several new ... "It was my intent Tuesday at our conference ... new type of rodenticide, but certainly not to give ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
Breaking Biology Technology:3 angelMD Startups Make Livestrong Big C Semi-finals 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Neogen comments on SenesTech 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... Renowned Clinical Authorities to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease ... a privately-held drug development company, announced today that it,has appointed ... a peptide fusion protein licensed from Amgen in December 2007 ...
... 5 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: PSX; Nasdaq: PXSL) ... on the afternoon of Wednesday 6th February. Dr ... morning to,review the quarter and answer investor questions., ... on Thursday 7th February,(Wednesday 6thFebruary, at 4.30pm (New ...
... CE Mark approval based on unprecedented results in ... ... Mass., Feb. 4 Tryton Medical, Inc., the leading,developer of ... company has received CE Mark approval for its,Side Branch Stent. ...
Cached Biology Technology:Anthera Pharmaceuticals Forms Scientific Advisory Board 2Tryton Medical Receives CE Mark Approval for its Side-Branch Stent 2
(Date:7/23/2014)... Mass. The U.S. Environmental Protection Agency (EPA) ... of the University of Massachusetts Amherst School of ... a three-year, $700,000 Science to Achieve Results (STAR) ... used by Native subsistence hunters in subarctic North ... smoke exposure and to provide culturally-relevant recommendations for ...
(Date:7/23/2014)... that urban "heat islands" are slowly killing red maples ... researchers have found warmer temperatures increase the number of ... significant tree pest by 300 percent, which in ... on urban trees. , "We,d been seeing higher numbers ... and now we know why," says Adam Dale, a ...
(Date:7/23/2014)... analysis of Antarctic fur seals, alongside decades of ... effect of climate change on a population of ... the findings show that the seals have significantly ... that are associated with climate conditions. Despite a ... fitness is not passing down through generations, leaving ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3
... acknowledge the need to obtain their energy supply from ... how his team have developed a new anaerobic digestion ... wind turbines. These reactors use a consortium of methanogenic ... produce biogas (a mixture of methane and carbon) which ...
... Much as an anthropologist can study populations of people ... social structures, some marine microbiologists read the genome of ... environments and lifestyles. Using a relatively new ... entire genomes of different populations of the same microbe ...
... to intestinal cancer in mice More than 50% ... cytomegalovirus (HCMV) infection. For most people, infection produces no symptoms ... a long time. HCMV infects many cell types in the ... research, led by Sergio Lira, at Mount Sinai School of ...
Cached Biology News:Microscopic solutions to world's biggest problems 2Genomic comparison of ocean microbes reveals East-West divide in populations 2Genomic comparison of ocean microbes reveals East-West divide in populations 3JCI online early table of contents: Oct. 11, 2010 2JCI online early table of contents: Oct. 11, 2010 3JCI online early table of contents: Oct. 11, 2010 4JCI online early table of contents: Oct. 11, 2010 5JCI online early table of contents: Oct. 11, 2010 6JCI online early table of contents: Oct. 11, 2010 7
... new MyiQ real-time PCR detection system offers ... common green fluorescent dyes such as FAM ... directly with the iCycler thermal cycler, offering ... Peltier-effect driven performance. The MyiQ real-time PCR ...
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... vascular proliferation, adhesion, and wound repair have ... adhesion receptors consists of at least 16 ... b subunit that associate in a non-covalent ... the integrin family are based upon the ...
Biology Products: